title: Appropriate invasive and conservative strategies for patients with non-ST elevation acute coronary syndromes.
abstract: OBJECTIVE
  This review focuses on recent developments in three controversial areas of management of acute coronary syndromes.
  
  
  RESULTS
  There are potential benefits of an early invasive treatment strategy (routine cardiac catheterization and revascularization when appropriate) in the elderly, who are at high risk for adverse outcomes and treatment-related complications following acute coronary syndromes. There are developments in the role of low-molecular-weight heparin agents in management of acute coronary syndromes in the modern treatment era, in which early coronary revascularization and use of other potent antiplatelet and antithrombin agents are common. Finally, this review looks at emerging data and controversy regarding the effects of intensive lipid-lowering treatment early after acute coronary syndrome. Recent clinical trials have yielded contradictory results.
  
  
  CONCLUSIONS
  This paper evaluates recent evidence in acute coronary syndromes regarding early invasive revascularization strategies in high risk elderly patients, and also discusses controversies regarding the role of low molecular weight heparin and intensive statin regimens.
authors.affiliation: The Donald W Reynolds Cardiovascular Clinical Research Center and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9047, USA.
authors.forename: Sameer K
authors.initials: SK
authors.lastname: Mehta
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
mesh_terms: D000208:Acute Disease; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D017115:Catheter Ablation / Q000379:methods*; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D019317:Evidence-Based Medicine; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D009204:Myocardial Revascularization; D012307:Risk Factors; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors